{
C4 Therapeutics Inc.

Companies

}
001122334455554433221100
001122334455554433221100

ubs lowers c4 therapeutics price target while maintaining neutral rating

UBS has lowered its price target for C4 Therapeutics, Inc. to $3.50 from $4 while maintaining a neutral rating. The clinical-stage biopharmaceutical company focuses on targeted protein degradation, utilizing its TORPEDO platform to develop small-molecule medicines, including candidates CFT7455 and CFT1946 for various cancers.
MarketScreener
C4 Therapeutics Inc. USA
Healthcare & Medicine, Market Report
14:26 03.03.2025
Trending
Subcategory
Corporate News Stock Market Updates Industry Trends Banking Regulations CEO Changes Finance Mergers & Acquisitions Global Financial Events Industry Mergers & Acquisitions Central Bank Actions Market Analysis and Predictions Workplace Trends Retail and Consumer Goods Startups & Entrepreneurship Financial Scams and Security Government Economic Policies Global Trade Developments Commodities Corporate Social Responsibility Energy Sector Developments Government Policies
Countries:
USA CHE DEU GBR CHN IND ARE FRA JPN AUS SAU ITA HKG ESP CAN AUT EGY SGP KWT DNK
Companies:
Credit Suisse Strategic Income I UBS Group AG JPMorgan Chase & Co. The Goldman Sachs Group, Inc. Wells Fargo & Company Bank of America Corporation Citigroup Inc. Morgan Stanley Barclays PLC Deutsche Bank RV Global PP Berkshire Hathaway Inc. Apple Inc. Tesla, Inc. Novartis AG Volkswagen AG BNP Paribas SA NVIDIA Corporation Microsoft Corporation Lloyds Banking Group plc Banco Santander, S.A.
Currencies:
United States Dollar Swiss Franc Euro British Pound Sterling Indian Rupee Chinese Yuan Japanese Yen United Arab Emirates Dirham Australian Dollar Egyptian Pound South Korean Won Malaysian Ringgit Saudi Riyal Hong Kong Dollar Danish Krone Vietnamese Đồng Polish Złoty Kuwaiti Dinar Filipino Peso Offshore Chinese Yuan
People:
Sergio Ermotti Donald Trump Colm Kelleher Elon Musk Warren Buffett Jakob Stark Bob Diamond Ariane Luthi Axel Lehmann Karin Keller-Sutter Robin Leopold Charles W. Scharf Vas Narasimhan Troy L Rohrbaugh Ralph Hamers Jennifer Piepszak Stacey Friedman Todd Tuckner Joe Biden Vasant Narasimhan

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.